AI and Prior Authorization: Promise, Peril, and the Path For

Introduction

Prior authorization (PA) is a cost‑containment tool used by insurers to approve or deny coverage for certain procedures, medications, or services before they are delivered. While intended to curb waste, PA has become a source of frustration for physicians, patients, and administrators alike. The average physician spends 10–15 minutes per request, and patients often face delays that can worsen outcomes.

Enter artificial intelligence. Machine‑learning models that can parse electronic health records (EHRs), predict utilization, and flag high‑risk cases appear poised to automate the tedious back‑and‑forth of PA. Yet the same technology that could speed up approvals might also embed bias, reduce transparency, and shift accountability away from human clinicians.

This post explores the dual possibilities—how AI could fix prior authorization and how it could make it worse—and offers a roadmap for responsible implementation.

---

How AI Could Fix Prior Authorization

1. Real‑time Decision Support

AI algorithms trained on large claims datasets can instantly evaluate whether a request meets payer criteria. Integrated into the EHR workflow, the system can pre‑populate forms, suggest alternative therapies that meet coverage guidelines, and provide clinicians with a confidence score for the likely outcome. Early pilots at Geisinger Health and Kaiser Permanente report a 30‑40% reduction in manual PA submission time.

2. Predictive Analytics for Utilization Management

Predictive models can identify patients who are most likely to benefit from a particular therapy, allowing payers to prioritize approvals for high‑value cases. By leveraging longitudinal data, AI can reduce unnecessary denials and focus resources on interventions with proven cost‑effectiveness.

3. Standardization Across Payers

One of the biggest pain points is the lack of uniformity among insurers. AI can act as a neutral intermediary, translating disparate payer rules into a common language. This standardization could be especially valuable for Medicare Advantage plans, where the Centers for Medicare & Medicaid Services (CMS) is experimenting with a unified PA platform powered by AI.

4. Reducing Administrative Burden

Automation of routine PA tasks frees clinicians to spend more time on direct patient care. A study published in Health Affairs (2024) estimated that AI‑driven PA could save $1.2 billion annually in provider labor costs across the United States.

---

How AI Could Make Prior Authorization Worse

1. Amplifying Existing Biases

Machine‑learning models inherit the biases present in training data. If historical PA decisions reflect inequities—such as higher denial rates for minority patients—AI may perpetuate or even exacerbate those disparities. Without rigorous bias audits, AI could become a black box that systematically disadvantages vulnerable groups.

2. Opacity and Lack of Explainability

Clinicians need to understand why a request is denied to appeal effectively. Many AI systems, especially deep‑learning models, provide probabilistic scores without transparent rationale. This opacity can erode trust and make it harder for providers to contest erroneous denials.

3. Shifting Accountability

When an AI system makes a recommendation, who is responsible for an incorrect denial? The payer, the software vendor, or the clinician who relied on the tool? This diffusion of accountability can lead to legal gray areas and may discourage providers from adopting the technology.

4. Over‑reliance on Algorithms

A tempting outcome is that payers might reduce human oversight, assuming the AI will catch all errors. However, healthcare is nuanced; edge cases—rare diseases, off‑label uses, or patient‑specific considerations—often require clinical judgment that an algorithm cannot replicate.

---

Real‑World Experiments and Lessons Learned

- UnitedHealth Group’s “AI‑PA” Pilot (2025): Deployed a natural‑language processing (NLP) engine to extract relevant clinical data from notes. The pilot cut average turnaround time from 7 days to 2.5 days but faced criticism after a spike in denials for patients with chronic kidney disease—a cohort underrepresented in the training set.

- CMS’s AI‑Enabled Medicare PA Initiative (2026): Partnered with IBM Watson Health to create a decision‑support tool for high‑cost imaging. Early results show a 15% increase in appropriate imaging utilization, yet the agency paused the rollout to conduct an equity impact assessment.

- Google DeepMind’s Clinical Pathway Optimizer (2024): Tested in a UK NHS trust for oncology drug approvals. While the system improved guideline adherence, clinicians reported difficulty understanding the algorithm’s “black‑box” recommendations, leading to a hybrid approach where AI suggestions were always reviewed by a pharmacist.

These examples underscore a crucial point: technology alone does not guarantee improvement; the surrounding governance, data quality, and stakeholder engagement determine success.

---

Recommendations for a Balanced Approach

1. Transparent Model Development – Publish model architecture, training data sources, and performance metrics. Use techniques like SHAP values to provide explainable outputs. 2. Bias Audits and Equity Monitoring – Conduct regular audits for disparate impact across race, gender, geography, and socioeconomic status. Adjust models proactively. 3. Human‑in‑the‑Loop Design – Keep clinicians in the decision loop, especially for high‑risk or atypical cases. AI should augment, not replace, clinical judgment. 4. Clear Liability Frameworks – Establish contractual and regulatory guidelines that delineate responsibility among payers, vendors, and providers. 5. Standardized Data Interoperability – Adopt FHIR‑based APIs to ensure that AI tools can access consistent, high‑quality data across EHR systems. 6. Stakeholder Collaboration – Involve patient advocacy groups, professional societies such as the American Medical Association (AMA), and payer coalitions in the design and rollout phases.

---

Looking Ahead

AI holds the promise of turning prior authorization from a bureaucratic hurdle into a clinical decision‑support tool that aligns cost containment with patient outcomes. However, without deliberate safeguards, the same technology could deepen inequities and erode trust.

The path forward is not binary—fix or worsen—but a continuum where ethical AI design, rigorous evaluation, and collaborative governance determine the net impact. As stakeholders continue to experiment, the ultimate measure of success will be whether patients receive the right care when they need it, without unnecessary administrative delay.

---

Author’s note: This post synthesizes publicly available information and does not represent the views of any specific organization.

Sources: https://undark.org/2026/07/15/medicare-prior-authorization-ai/